Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival
with conventional chemotherapy and newer regimens are greatly needed. It has been noted that
patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold
significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new
inhibitor of the VEGFR-2, has shown favorable action in NSCLC.